XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues:        
Royalties and other revenue $ 20 $ 9 $ 20 $ 76
Total revenues 14,182 1,750 44,310 4,527
Operating expenses:        
Cost of sales 10 71 73 268
Research and development 18,757 25,780 49,806 57,795
Selling, general and administrative, including stock-based compensation of $1,612, $1,341, $4,656 and $7,229 respectively 7,602 39,592 28,562 110,844
Total operating expenses 26,369 65,443 78,441 168,907
Loss from operations (12,187) (63,693) (34,131) (164,380)
Interest and other expense  (2,155) (4,562) (6,308) (11,721)
Interest income and other 1,573 3,444 5,628 9,464
Net loss $ (12,769) $ (64,811) $ (34,811) $ (166,637)
Net loss per common share, basic (usd per share) $ (0.04) $ (0.18) $ (0.10) $ (0.54)
Net loss per common share, diluted (usd per share) $ (0.04) $ (0.18) $ (0.10) $ (0.54)
Weighted average common shares outstanding, basic (in shares) 363,399 361,492 362,927 306,109
Weighted average common shares outstanding, diluted (in shares) 363,399 361,492 362,927 306,109
Other comprehensive income (loss):        
Unrealized gain (loss) on investments $ 43 $ 542 $ (90) $ 318
Comprehensive loss (12,726) (64,269) (34,901) (166,319)
Product        
Revenues:        
Net product and licensing revenue 1,008 1,741 3,592 4,451
License        
Revenues:        
Net product and licensing revenue 13,154 $ 0 40,698 $ 0
License | Novo Nordisk        
Revenues:        
Net product and licensing revenue $ 13,200   $ 40,700